Evidence map›Paper›PMID 41969333›Full record

ArticleEClinicalMedicine2026

Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study.

Victoria A Sanchez, Paul C Dinh, Patrick O Monahan, Chunkit Fung, Sandra Althouse, Tim Stump, Jennessa Rooker, M Eileen Dolan, Darren R Feldman, Robert J Hamilton and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Victoria A SanchezDepartment of Otolaryngology - Head and Neck Surgery, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 73, Tampa, FL, 33612, USA.
Paul C DinhDivision of Hematology/Oncology, Indiana University School of Medicine, 535 Barnhill Dr, Indianapolis, IN, 46202, USA.
Patrick O MonahanDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, 1050 Wishard Blvd, Indianapolis, IN, 46202, USA.
Chunkit FungDivision of Hematology and Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY, 14642, USA.
Sandra AlthouseDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, 1050 Wishard Blvd, Indianapolis, IN, 46202, USA.
Tim StumpDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, 1050 Wishard Blvd, Indianapolis, IN, 46202, USA.
Jennessa RookerCollege of Nursing, University of South Florida, 12912 USF Health Dr, Tampa, FL, 33612, USA.
M Eileen DolanDepartment of Medicine, University of Chicago, 5841 South Maryland Ave, MC 6092, Chicago, IL, 60637, USA.
Darren R FeldmanDepartment of Medicine (Genitourinary Oncology Service), Memorial Sloan Kettering Cancer Center, 353 East 68th St, New York, NY, 10065, USA.
Robert J HamiltonDivision of Urology, Princess Margaret Cancer Centre, 3-130, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Phillip M PierorazioDepartment of Surgery, University of Pennsylvania, Penn Medicine University City, 3737 Market St, Philadelphia, PA, 19104, USA.
Neil E MartinDepartment of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, 450 Brookline Ave, Boston, MA, 02215, USA.
Robert HuddartInstitute of Cancer Research, 123 Old Brompton Rd, London, SW7 3RP, UK.
Christian KollmannsbergerDepartment of Medical Oncology, BC Cancer Vancouver Center, 600 West 10th Ave, 4th Floor, Vancouver, BC, V5Z 4E6, Canada.
James RootDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 160 East 53rd St, New York, NY, 10022, USA.
Howard D SessoDivision of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, 900 Commonwealth Ave, Boston, MA, 02115, USA.
Mandy WeinzierlRehabilitation Services, Indiana University Health, 705 Riley Hospital Dr, Indianapolis, IN, 46202, USA.
Lawrence H EinhornDivision of Hematology/Oncology, Indiana University School of Medicine, 535 Barnhill Dr, Indianapolis, IN, 46202, USA.
Robert D FrisinaDepartment of Medical Engineering, University of South Florida, 4202 East Fowler Ave, ENG 030, Tampa, FL, 33620, USA.
Lois B TravisDivision of Hematology/Oncology, Indiana University School of Medicine, 535 Barnhill Dr, Indianapolis, IN, 46202, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Cisplatin is broadly used, but it is nephrotoxic and ototoxic. No large-scale investigation has analysed cisplatin-related ototoxicity while considering quantified renal function, cumulative dose, comorbidities, and modifiable risk factors. Our aim was to fill this knowledge gap. Methods: The Platinum Study is a well-characterised multicentre cohort study of cisplatin-treated testicular cancer survivors enrolled 2012-18 in eight academic cancer centres in the USA, Canada, and the UK, with follow-up ongoing. Measures include audiometrically assessed hearing (0.25-12 kHz), real-world speech-in-noise perception, and hearing loss progression. Multivariable analyses evaluated associations of audiometrically-assessed hearing with estimated glomerular filtration rate (eGFR), comorbidities, health-behaviours, and cisplatin dose. Mediation analyses tested direct and indirect eGFR contributions to ototoxicity and eGFR-dose interactions. Findings: Among 1422 survivors (median age 38 years, IQR 31-47), ototoxicity affected 1061 (75%), and audiometrically-assessed hearing was significantly associated with cumulative cisplatin dose (β = 8.72 per 100 mg/m Interpretation: Cisplatin's dose-dependent ototoxicity is amplified by its nephrotoxicity, with the dose-response becoming stronger as eGFR worsens. Given age-related declines in both eGFR and hearing, follow-up of cisplatin-treated survivors should monitor both, and include strict control of cardiovascular risk factors. Statin use for hypercholesterolaemia appeared protective against hearing loss progression, suggesting a potential therapeutic intervention for reducing long-term auditory complications in this population. Funding: The National Cancer Institute.

Indexed as

Cancer survivorshipCisplatin ototoxicityNephrotoxicityRenal functionSensorineural hearing lossSpeech-in-noise perception

Identifiers

PMID41969333
PMCPMC13068843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.